|
MPZL1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.86769488763616E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.94084806191131E-12 |
| Normal-vs-Stage2 |
3.42770000161252E-08 |
| Normal-vs-Stage3 |
3.400200E-04 |
| Normal-vs-Stage4 |
9.74980000000292E-05 |
| Stage1-vs-Stage2 |
3.362600E-01 |
| Stage1-vs-Stage3 |
1.119830E-01 |
| Stage1-vs-Stage4 |
6.863000E-01 |
| Stage2-vs-Stage3 |
4.661500E-02 |
| Stage2-vs-Stage4 |
3.176200E-01 |
| Stage3-vs-Stage4 |
4.412000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.01009986433576E-10 |
| Normal-vs-AfricanAmerican |
2.557000E-01 |
| Normal-vs-Asian |
4.15799999999855E-05 |
| Caucasian-vs-AfricanAmerican |
5.210000E-02 |
| Caucasian-vs-Asian |
9.221400E-01 |
| AfricanAmerican-vs-Asian |
1.001040E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.77660000547186E-08 |
| Normal-vs-Female |
2.37230235455854E-11 |
| Male-vs-Female |
5.451200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.5642599982566E-12 |
| Normal-vs-Age(41-60Yrs) |
1.01760000426054E-09 |
| Normal-vs-Age(61-80Yrs) |
4.0105000000068E-05 |
| Normal-vs-Age(81-100Yrs) |
5.571200E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.909800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.323430E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.924200E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.985800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.757430E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.504600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.357000E-01 |
| Classical-VS-Follicular |
4.06520000000299E-05 |
| Classical-VS-Other |
3.310200E-01 |
| Classical-VS-Normal |
9.52390000197312E-08 |
| Tall-VS-Follicular |
1.901680E-02 |
| Tall-VS-Other |
4.360000E-01 |
| Tall-VS-Normal |
6.795400E-03 |
| Follicular-VS-Other |
6.898800E-01 |
| Follicular-VS-Normal |
5.17363929475323E-14 |
| Other-VS-Normal |
7.413400E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.40452102673316E-12 |
| Normal-vs-N1 |
8.84430000014369E-07 |
| N0-vs-N1 |
7.709800E-01 |
|
|
